1.66
price up icon18.57%   0.26
after-market Handel nachbörslich: 1.63 -0.03 -1.81%
loading

Protalix BioTherapeutics Inc. Aktie (PLX) Neueste Nachrichten

pulisher
Nov 15, 2024

PLX: Self-Sustaining Rise to Lead in Renal Rare Disease - Yahoo Finance

Nov 15, 2024
pulisher
Nov 15, 2024

Protalix BioTherapeutics, Inc. (AMEX:PLX) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 15, 2024
pulisher
Nov 15, 2024

Protalix BioTherapeutics Inc. (PLX) Quarterly 10-Q Report - Quartzy

Nov 15, 2024
pulisher
Nov 15, 2024

Protalix: Q3 Earnings Snapshot - New Haven Register

Nov 15, 2024
pulisher
Nov 15, 2024

Protalix BioTherapeutics Inc (PLX) Q3 2024 Earnings Call Highlights: Revenue Surge and ... - Yahoo Finance

Nov 15, 2024
pulisher
Nov 14, 2024

Protalix BioTherapeutics Reports Strong Q3 2024 Results - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results - citybiz

Nov 14, 2024
pulisher
Nov 07, 2024

Protalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024 - The Malaysian Reserve

Nov 07, 2024
pulisher
Nov 07, 2024

Protalix BioTherapeutics Sets Q3 2024 Earnings Call for November 14 | PLX Stock News - StockTitan

Nov 07, 2024
pulisher
Oct 31, 2024

Accolade And 2 Other Penny Stocks To Watch On US Exchanges - Simply Wall St

Oct 31, 2024
pulisher
Oct 29, 2024

Fabry Disease Market to grow at a CAGR of ~6% by 2032, analyzes - openPR

Oct 29, 2024
pulisher
Oct 29, 2024

Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GuruFocus.com

Oct 29, 2024
pulisher
Oct 28, 2024

Protalix BioTherapeutics Announces Repayment of Outstanding Seni - GuruFocus.com

Oct 28, 2024
pulisher
Oct 25, 2024

PLXProtalix BioTherapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Oct 25, 2024
pulisher
Oct 25, 2024

Protalix BioTherapeutics to Present Phase I PRX-115 Data in Late-Breaking Poster at ACR Convergence 2024 - PR Newswire

Oct 25, 2024
pulisher
Oct 24, 2024

OTC Markets Hosts Virtual Investor Presentation with Dror Bashan, President & CEO of Protalix Biotherapeutics, and John Vandermosten, Senior Analyst at Zacks SCR - Zacks Small Cap Research

Oct 24, 2024
pulisher
Sep 16, 2024

Protalix BioTherapeutics to Present at the Life Sciences Investor Forum September 19, 2024 - GlobeNewswire

Sep 16, 2024
pulisher
Sep 11, 2024

Protalix BioTherapeutics Announces Repayment of Outstanding Senior Secured Convertible Promissory Notes - Kilgore News Herald

Sep 11, 2024
pulisher
Sep 04, 2024

Is Protalix BioTherapeutics Inc. (PLX) worth investing in despite its overvalued state? - US Post News

Sep 04, 2024
pulisher
Sep 04, 2024

Protalix BioTherapeutics Inc. (PLX) Stock: A Comprehensive 52-Week Review - The InvestChronicle

Sep 04, 2024
pulisher
Sep 04, 2024

Is Protalix BioTherapeutics, Inc. (PLX) The Best Rated Penny Stock To Buy According to Analysts? - Yahoo Finance UK

Sep 04, 2024
pulisher
Sep 04, 2024

Protalix BioTherapeutics clears debt, secures operational runway - Investing.com

Sep 04, 2024
pulisher
Sep 03, 2024

Protalix BioTherapeutics clears debt, secures operational runway By Investing.com - Investing.com Canada

Sep 03, 2024
pulisher
Sep 03, 2024

Protalix says FDA okays drug-trial design - Reuters

Sep 03, 2024
pulisher
Aug 28, 2024

10 Best Rated Penny Stocks To Buy According to Analysts - Insider Monkey

Aug 28, 2024
pulisher
Aug 26, 2024

Protalix BioTherapeutics, Inc. Expected to Post FY2024 Earnings of $0.06 Per Share (NYSE:PLX) - MarketBeat

Aug 26, 2024
pulisher
Aug 26, 2024

Fabry Disease Market to Sour at a CAGR of ~6% by 2032, estimates - openPR

Aug 26, 2024
pulisher
Aug 26, 2024

Analyzing Protalix BioTherapeutics (NYSE:PLX) & Adaptimmune Therapeutics (NASDAQ:ADAP) - Defense World

Aug 26, 2024
pulisher
Aug 26, 2024

Protalix BioTherapeutics, Inc. to Post FY2024 Earnings of $0.06 Per Share, Zacks Small Cap Forecasts (NYSE:PLX) - Defense World

Aug 26, 2024
pulisher
Aug 22, 2024

PLX: A Focus on Renal Rare Disease - Yahoo Finance

Aug 22, 2024
pulisher
Aug 19, 2024

Protalix BioTherapeutics to Announce Second Quarter 2022 Financial and Business Results Conference Call on August 15, 2022 - BioSpace

Aug 19, 2024
pulisher
Aug 16, 2024

Protalix BioTherapeutics (NYSE:PLX) Releases Quarterly Earnings Results, Misses Estimates By $0.05 EPS - Defense World

Aug 16, 2024
pulisher
Aug 15, 2024

Protalix BioTherapeutics (NYSE:PLX) Announces Quarterly Earnings Results, Misses Expectations By $0.05 EPS - MarketBeat

Aug 15, 2024
pulisher
Aug 15, 2024

Protalix BioTherapeutics to Release Third Quarter 2021 Financial Results and Provide a Financial and Business Update on November 15, 2021 - BioSpace

Aug 15, 2024
pulisher
Aug 15, 2024

Protalix BioTherapeutics Inc (PLX) Q2 2024 Earnings Call Transcr - GuruFocus.com

Aug 15, 2024
pulisher
Aug 15, 2024

Protalix BioTherapeutics Inc. (PLX) Stock: Uncovering 52-Week Market Trends - The InvestChronicle

Aug 15, 2024
pulisher
Aug 15, 2024

Earnings call: Protalix reports progress on PRX-115 and stable finances - Investing.com Australia

Aug 15, 2024
pulisher
Aug 15, 2024

Protalix BioTherapeutics, Inc. (AMEX:PLX) Q2 2024 Earnings Call Transcript - Insider Monkey

Aug 15, 2024
pulisher
Aug 15, 2024

Financial Health Report: Protalix BioTherapeutics Inc. (PLX)’s Ratios Tell a Tale - The Dwinnex

Aug 15, 2024
pulisher
Aug 15, 2024

Protalix: Q2 Earnings Snapshot - Darien Times

Aug 15, 2024
pulisher
Aug 15, 2024

Protalix BioTherapeutics to Present at the 2024 BIO International Convention - Longview News-Journal

Aug 15, 2024
pulisher
Aug 14, 2024

Protalix BioTherapeutics to Announce Second Quarter 2024 Financial and Business Results on August 14, 2024 - Longview News-Journal

Aug 14, 2024
pulisher
Aug 14, 2024

Protalix BioTherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com

Aug 14, 2024
$18.98
price up icon 3.66%
$76.97
price up icon 1.45%
$39.51
price up icon 7.22%
$359.21
price down icon 1.11%
$187.69
price down icon 0.81%
$101.87
price up icon 2.16%
Kapitalisierung:     |  Volumen (24h):